ATE240734T1 - Zubereitung von xanthinderivaten als feste dispersion - Google Patents

Zubereitung von xanthinderivaten als feste dispersion

Info

Publication number
ATE240734T1
ATE240734T1 AT96916342T AT96916342T ATE240734T1 AT E240734 T1 ATE240734 T1 AT E240734T1 AT 96916342 T AT96916342 T AT 96916342T AT 96916342 T AT96916342 T AT 96916342T AT E240734 T1 ATE240734 T1 AT E240734T1
Authority
AT
Austria
Prior art keywords
solid dispersion
preparation
xanthinderivates
hxdrogen
hxdroxy
Prior art date
Application number
AT96916342T
Other languages
English (en)
Inventor
Makoto Kigoshi
Tomoaki Masada
Yasuhiko Ueno
Yasuhiro Ishikawa
Eiji Hayakawa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE240734T1 publication Critical patent/ATE240734T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96916342T 1995-07-26 1996-06-07 Zubereitung von xanthinderivaten als feste dispersion ATE240734T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19005895 1995-07-26
PCT/JP1996/001555 WO1997004782A1 (en) 1995-07-26 1996-06-07 Solid dispersion or solid dispersion preparation of xanthine derivatives

Publications (1)

Publication Number Publication Date
ATE240734T1 true ATE240734T1 (de) 2003-06-15

Family

ID=16251650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916342T ATE240734T1 (de) 1995-07-26 1996-06-07 Zubereitung von xanthinderivaten als feste dispersion

Country Status (9)

Country Link
US (1) US6254889B1 (de)
EP (1) EP0784974B1 (de)
JP (1) JP3938938B2 (de)
AT (1) ATE240734T1 (de)
DE (1) DE69628276T2 (de)
DK (1) DK0784974T3 (de)
ES (1) ES2199289T3 (de)
PT (1) PT784974E (de)
WO (1) WO1997004782A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US7125565B2 (en) * 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US20030082231A1 (en) * 2001-02-02 2003-05-01 Cheryl Kos Coating for orally administered compositions
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP1479300B1 (de) * 2002-02-22 2009-10-21 Ajinomoto Co., Inc. Aminosäurepulver und verfahren zu seiner herstellung
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
EP1932529A1 (de) 2003-04-25 2008-06-18 Novacardia, Inc. Verfahren zur verbesserten Harnausscheidung bei Personen mit beeinträchtiger Nierenfunktion
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
CN1859913A (zh) * 2003-04-25 2006-11-08 美国诺华卡迪亚公司 改善肾功能损伤个体多尿症的方法
AU2004236101B2 (en) * 2003-05-09 2010-11-11 Kyowa Kirin Co., Ltd. Microcrystal
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
US20080312587A1 (en) * 2005-06-10 2008-12-18 Gruenethal Gmbh System for the Oral Administration of Solids to Persons Suffering from Dementia
CA2633372A1 (en) 2005-12-14 2007-06-21 Kyowa Hakko Kogyo Co., Ltd. Easily absorbed oral preparations of xanthine derivatives
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア,インク. Aa1raの低頻度投与を含む腎機能の長期間にわたる改善
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
EP2240162A4 (de) 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
KR20100124710A (ko) * 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
JP2015531749A (ja) 2012-06-21 2015-11-05 メイン ファーマ インターナショナル プロプライエタリー リミテッドMayne Pharma International Pty.Ltd. イトラコナゾール組成物及び投与剤形、並びにその使用方法
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TWI780270B (zh) 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
EP3841086B1 (de) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen zur behandlung von medizinischen störungen im zusammenhang mit komplementfaktor d
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ, インコーポレーテッド 医学的障害の治療のための大環状化合物
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
CN114845708A (zh) 2019-12-19 2022-08-02 乔治亚州大学研究基金会 用于治疗细菌感染和增强抗生素的化合物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ, インコーポレーテッド 補体因子d媒介障害の処置用のヘテロアリール化合物
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
WO1988000051A1 (en) * 1986-06-24 1988-01-14 Racz Istvan Proceeding for the production of pharmaceutical preparations of high gastric acid binding capacity, of retarded effect and of increased bioavailability
JP2521461B2 (ja) 1987-03-10 1996-08-07 エスエス製薬株式会社 持続性錠剤
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.

Also Published As

Publication number Publication date
WO1997004782A1 (en) 1997-02-13
PT784974E (pt) 2003-09-30
US6254889B1 (en) 2001-07-03
JP3938938B2 (ja) 2007-06-27
EP0784974A4 (de) 2000-09-27
DK0784974T3 (da) 2003-09-01
ES2199289T3 (es) 2004-02-16
EP0784974A1 (de) 1997-07-23
EP0784974B1 (de) 2003-05-21
DE69628276T2 (de) 2004-04-08
DE69628276D1 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
DE69628276D1 (de) Zubereitung von xanthinderivaten als feste dispersion
PT705833E (pt) Derivado de dc-89
ATE243697T1 (de) Substitutierte heterozyclische derivate als crf antagonisten
EP0731106A4 (de) Neue peptid-derivate
AU9281198A (en) Benzofuran derivatives
DK0695755T3 (da) Pyrrolocarbazoler
EP0632038A4 (de) Methotrexat-derivate.
DK0958821T3 (da) Fedtemulsion, der indeholder xanthinderivat
ATE151073T1 (de) Pyridincarboximidamide und deren anwendung
ID25477A (id) Turunan-turunan spiropiperidin
EP0676399A4 (de) Methotrexat-derivate.
ES2149180T3 (es) Derivado de pirazolotiazolopirimidina.
EP0994111A4 (de) Tetrahydrofuranderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0784974

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee